Friday, September 29, 2023
Quris- AI, the artificial intelligence (AI) innovator revolutionizing the pharmaceutical sector, today announced that it is a leading science and technology company . announced the expansion of its collaboration with Merck KGaA ( Darmstadt, Germany). This follows the success of the first collaboration, a preclinical study to assess the ability of CrisAI to predict drug toxicity compared to traditional in vitro and in vivo approaches .
Merck will then further leverage the capabilities of KrisAI's platform to effectively identify the hepatotoxicity risks of a range of new drug candidates. Merck then has the option to obtain exclusive licenses for specific disease areas for up to five years. If Merck exercises its option, KrisAI may receive an undisclosed amount.
“Based on the results of our initial collaboration, we will explore how the BioAI platform can advance our drug development and testing programs and work toward an AI-enabled IND process that reduces reliance on animal testing. We look forward to this," said Danny Bar-Zohar, head of global research and development for Merck's healthcare business. “If we can focus more on developing safe and effective new drug candidates, we can significantly reduce time and costs.”
Pre-clinical pilot studies demonstrated that KrisAI's platform can accurately predict which drugs cause drug-induced liver injury. KRISAI's BioAI platform (29 granted and pending patents) is based on KRISAI's highly predictive proprietary data generated from an AI-based patient-on-chip platform. Achieve best-in-class drug safety through advanced machine learning and generative AI models trained on This dramatically speeds up drug development, significantly reduces costs, and avoids the major blind spots of traditional animal testing.
"The vast majority of new drug candidates have failed even in clinical trials. Advances in technology are poised to bring about a much-needed change in drug development." Chris AI Chief Executive Officer Dr. Isaac Bentwich, CEO of “Accurately predicting the safety of new drugs can significantly shorten drug development and time to market, while significantly reducing risks and associated costs. By partnering with them, we look forward to continuing to contribute to the advancement of drug development."
About Quris -AI Quris-AI, the world's first Bio-AI clinical prediction platform, conducts business activities aimed at ensuring the safety of new drugs. The company is pioneering clinical trials on a chip, revolutionizing the drug development process and testing thousands of new drug candidates on "patients on a chip." Its fully automated, self-learning AI platform accurately predicts the clinical safety and efficacy of new drugs faster and more cost-effectively than ever before, while minimizing animal testing.
For media inquiries, please contact:
Erica Camilo
Connexa Communications (Chris AI)
1.610.639.5644
[email protected]
